|
Post by kball on Mar 4, 2015 6:47:41 GMT -5
Up 18% since 12/31.
A little more than Apple which started the year about 110
|
|
|
Post by mnholdem on Mar 4, 2015 9:30:33 GMT -5
MannKind, from the viewpoint of both ethical and non-ethical traders, represents a tremendous opportunity to make money.
But this window is closing, and closing fast, as years of scant information are about to be replaced by cold, hard sales figures... "can I get an Amen, brother?" During this final period of silence by MannKind and Sanofi, the investment community will contemplate whether Afrezza (and by association, MannKind) will succeed or fail among diabetics. How long will it take to know the answer? I don't know.
It's easy for Goldman-Sachs to take a crayon and draw a graph, especially when Sanofi is not about to publicly disclose its marketing strategy for its competitors to see.
Today, there are two things that I am confident I can predict with ABSOLUTELY 100% certainty.
1. For as long as information is lacking, the Wall Street pundits and investment analysts will continue to "fill in the blanks" with answers of their own, the purpose being for their own gain - not yours.
2. This is the time where the rubber meets the road and all your due diligence pays off. That diligence includes listening to the advice of some experienced investors here on ProBoards who, for example, recognize what GS is doing because they've seen it happen before.
|
|
|
Post by obamayoumama on Mar 4, 2015 20:15:19 GMT -5
Can anyone guess how many companies Jay Olson issued research reports on in the last 3 years? 1 company, MNKD. His first report was a neutral rating on MNKD on November 19th. Now he issued a sell rating on March 3rd. I called Jay to see if he is only covering MNKD and no other companies at this time. He said that is correct. Most analyst cover more that five companies. Got me to thinking. Something isn't right! I have to wonder if he started MNKD with a neutral which at the time put downward pressure on the stock price. Is he a shill for the shorts, interesting right when it was known that Invesco had a order for 2.5 mm shares to purchase to rebalance a fund and Jay issues a sell recommendation.
|
|
|
Post by BlueCat on Mar 4, 2015 20:44:57 GMT -5
Does he have a resume as an analyst before GS?
If not, it means he's probably expendable. A shill only. And someone GS could discharge if there was a hint of trouble. (and then comp him handsomely for the trouble).
Yuck.
|
|
|
Post by obamayoumama on Mar 4, 2015 21:19:43 GMT -5
Does he have a resume as an analyst before GS? If not, it means he's probably expendable. A shill only. And someone GS could discharge if there was a hint of trouble. (and then comp him handsomely for the trouble). Yuck. He got his research license in July 2012. It smells that he has only is following one company. Think that his report was to protect their Hedge Fund Clients.
|
|
|
Post by otherottawaguy on Mar 5, 2015 10:41:19 GMT -5
poormeil:
Its time to average down brother.
OOG
|
|